Research Paper Volume 13, Issue 8 pp 11595—11609

Figure 6. Exo-MSCs-M.tb induced pro-inflammatory response through TLRs. (A) The protein levels of TLR2, TLR4, and MyD88 in the lung of TLR2^-/-, TLR4^-/-, and MyD88 ^-/- mice, respectively. (B) TNF-α levels in the lung of TLR2^-/- mice treated with Exo-MSCs-M.tb (20μg) (20μg), as detected by ELISA assay 24 hours after exosome treatment. (C) TNF-α levels in the lung of TLR4^-/- mice treated with Exo-MSCs-M.tb (20μg), as detected by ELISA assay 24 hours after exosome treatment. (D) TNF-α levels in the lung of MyD88 ^-/- mice treated with control (PBS), Exo-MSCs (20μg), and Exo-MSCs-M.tb (20μg), as detected by ELISA assay 24 hours after exosome treatment. (E) IL-12 p40 levels in the lung of C57BL/6 mice treated control (PBS), Exo-MSCs (20μg), and Exo-MSCs-M.tb (20μg). (F) TNF-α levels in the lung of C57BL/6 mice treated with control (PBS), Exo-MSCs (20μg), and Exo-MSCs-M.tb (20μg). (G) Neutrophil infiltration of C57BL/6 mice treated with control (PBS), Exo-MSCs (20μg), and Exo-MSCs-M.tb (20μg). *p < 0.05.